Semaglutide Maintenance Dose: Personalized Dosing Guide

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide maintenance doses range from 0.5 to 2.4 mg weekly, with most patients stabilizing at 1.0 to 2.0 mg for sustained weight loss. Individual tolerance and response vary significantly based on metabolic factors, baseline weight, and genetic predispositions in GLP-1 receptor pathways.

Effective long-term weight management requires more than a single dose—it demands precision alignment between medication, lifestyle, and your metabolic profile. PlexusDx emphasizes that understanding your genetic and biomarker context can support a more informed conversation with your provider about finding your optimal maintenance level.

How Semaglutide Maintenance Dosing Is Established

Semaglutide dosing follows a graduated titration schedule: weeks 1–4 start at 0.25 mg, increasing by 0.25 mg every four weeks until reaching a target maintenance dose. Most patients achieve clinical benefit at 1.0 to 2.0 mg weekly, though some respond to lower or higher doses based on tolerance and weight-loss goals.

The maintenance phase typically begins after 16–20 weeks of titration. At this point, your provider assesses your weight loss trajectory, side-effect profile, and appetite suppression to confirm the optimal dose. Staying at maintenance dosing for 12 weeks or longer helps establish whether your body has reached a metabolic set point or continues responding.

Maintenance Dose Ranges and Individual Response Variability

Not all patients achieve the same degree of weight loss at identical doses. Clinical trials show 1.0 mg achieves 5–7% body weight reduction, while 2.4 mg achieves 12–18% in responders. However, approximately 20–30% of patients experience plateau effects, necessitating dose adjustment or protocol change based on biomarker response.

Maintenance Dose (mg/week)	Average Weight Loss Range	Common Clinical Timeline	Biomarker Monitoring Relevance
0.5–1.0 mg	5–7% body weight	12–24 weeks at maintenance	Monitor fasting glucose, HbA1c if diabetic; assess appetite effect
1.5–2.0 mg	10–15% body weight	16–32 weeks at maintenance	Track lipid panel, inflammatory markers; evaluate GI tolerability
2.4 mg (maximum)	12–18% body weight	20+ weeks at maintenance	Assess muscle mass retention; monitor caloric intake adequacy
Dose reduction if needed	Varies; often 3–5%	Ongoing after adjustment	Re-evaluate GLP1R genetic predisposition context if plateau occurs

Biomarkers That Inform Maintenance-Dose Optimization

Beyond weight, several biomarkers guide whether your maintenance dose is appropriate. Fasting glucose, HbA1c, triglyceride levels, and inflammatory markers (CRP, IL-6) often improve during semaglutide therapy, signaling metabolic benefit. If these markers plateau or decline unexpectedly, your provider may consider dose escalation or investigation of adherence and lifestyle factors.

Body composition changes matter too: rapid muscle loss during weight loss suggests your maintenance dose may be suppressing appetite excessively relative to your protein intake and exercise capacity. A provider-coordinated assessment of lean body mass retention, coupled with dietary optimization, can help preserve metabolic health during long-term treatment.

Genetic Predispositions and Maintenance-Dose Response

Genetic variants in the GLP1R gene and GIPR pathway influence how your body metabolizes and responds to semaglutide. Certain allele combinations may correlate with faster initial weight loss, stronger appetite suppression, or higher likelihood of gastrointestinal side effects—all factors your provider should consider when confirming your maintenance dose.

PlexusDx's Precision Peptide Genetic Test examines variants like GLP1R rs6923761 and GIPR rs1800437 to provide context about your peptide pathway predispositions. Understanding whether you carry variants associated with heightened semaglutide sensitivity may help your provider anticipate tolerance patterns and refine your long-term maintenance strategy with greater confidence.

Safety, Eligibility, and When Maintenance Dosing Applies

Semaglutide maintenance therapy is appropriate for adults with overweight or obesity, or type 2 diabetes, who have completed titration and shown weight loss or metabolic benefit. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or active thyroid malignancy. Pregnancy, breastfeeding, and severe renal/hepatic impairment require provider reassessment.

Common maintenance-phase side effects—nausea, constipation, reduced appetite, mild diarrhea—typically diminish over weeks to months. If severe GI symptoms persist at your maintenance dose, your provider may reduce dosing, optimize hydration and fiber intake, or transition to an alternative treatment. Regular follow-up appointments (every 3–6 months) help monitor efficacy and safety throughout the maintenance period.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your genetic predispositions in key peptide pathways—including GLP1R and GIPR variants—that can influence how your body responds to semaglutide. This information, when interpreted with a qualified healthcare provider, may support a more personalized conversation about your ideal maintenance dose and expected timeline for sustained weight loss.

The Precision Peptide Genetic Test reveals predispositions in peptide genetic pathways, not exact medication response. Variants such as GLP1R rs6923761 and GIPR rs1800437 may correlate with differences in semaglutide sensitivity, appetite suppression strength, or side-effect likelihood. However, genetics account for only part of your response; lifestyle, adherence, and overall metabolic health remain equally important determinants of maintenance-dose success.

Understanding your genetic context alongside your biomarker profile—fasting glucose, weight-loss trajectory, lean body mass, and inflammatory markers—can help you and your provider build a more comprehensive picture of whether your current maintenance dose is optimal. This precision-wellness approach supports more evidence-informed adjustments if you experience a plateau or unexpected side effects.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.